We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Spiral Occlusion Device Promotes Closure of Vascular Defect

By HospiMedica International staff writers
Posted on 07 Oct 2013
A novel percutaneous closure device has been specifically designed to occlude patent ductus arteriosus (PDA) heart defects.

The Nit-Occlud PDA system is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size PDA defects with a minimum angiographic diameter of less than 4 mm. More...
The device is delivered percutaneously, and can be repositioned as needed before final deployment. The spiral device is comprised of an outer nitinol coil wire wound around an inner one; the coil self-expands when unsheathed, plugging the gap, and preventing the blood from mixing. Tissue growth over the implant eventually allows it to become part of the pulmonary artery.

The Nit-Occlud PDA system is available in three different types and a broad variety of sizes. The two primary benefits of the device are that the coil occluder has a stiffness gradient, increasing from the pulmonary to aortal side, thus allowing the coil to conform to uniquely varying anatomy; secondly, the spiral shape of the coil also ensures the occluder can be implanted accurately and easily. The Nit-Occlud PDA system is a product of pfm medical (Köln, Germany), and has been approved by the US Food and Drug Administration (FDA).

PDA is a congenital disorder in the heart wherein a neonate's ductus arteriosus fails to close, remaining patent (open), thus allowing part of the oxygenated blood from the left heart to return to the lungs by flowing from the aorta to the pulmonary artery. Early symptoms are uncommon, but in the first year of life include increased work of breathing and poor weight gain. With age, PDA may lead to congestive heart failure (CHF), if left uncorrected. Neonates without adverse symptoms may simply be monitored as outpatients, while symptomatic PDA can be treated with both surgical and non-surgical methods.

Related Links:
pfm medical


Gold Member
Blood Gas Analyzer
i-Check200
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Digital Radiography System (Ceiling Free)
Digix CF Series
Patient Preoperative Skin Preparation
BD ChloraPrep
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.